O-RAN ALLIANCE Announces New Board Member and Introduces Minimum Viable Plan to Expedite the Delivery of Essential O-RAN Functions
As of February 23, 2021, the O-RAN ALLIANCE welcomes DISH Network as a new member of its Board of Directors.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210316005553/en/
O-RAN Logical Architecture (Graphic: Business Wire)
“Carriers around the world are recognizing the importance of building next-generation, programmable networks that are open, intelligent and flexible, making the work of the O-RAN ALLIANCE more critical than ever,” said Sidd Chenumolu, DISH vice president of technology development. “At DISH, we are in a unique position as we build a 5G network entirely upon O-RAN standards, and the work of this organization creates a unified roadmap as our partners join us in developing a disaggregated and open RAN. We look forward to playing a continued role in the success of the O-RAN ALLIANCE and the development of standards that enhance connectivity worldwide.”
O-RAN ALLIANCE’s Minimum Viable Plan (MVP) Towards Commercial O-RAN Solutions
O-RAN’s specification effort, open software development, as well as testing and integration, will focus on priorities set by its operator members. This approach will allow the O-RAN ecosystem players to prioritize the delivery of a minimum viable set of end-to-end O-RAN solutions applicable in commercial networks.
The first release of the MVP includes already published specifications and additional work items in the area of:
- Open fronthaul specifications provide fully specified control, user and synchronization interface, management plane interface between O-RU and O-DU, and relevant conformance and interoperability tests, enabling multi-vendor interoperability.
- Open transport defines the requirements of xhaul transport, proposes the best practices of deploying WDM and IP technologies in xhaul.
- Open hardware offers hardware reference designs for different modes of indoor picocell, outdoor microcell, outdoor Macrocell and open fronthaul gateway to accelerate the use of whitebox and facilitate RAN ecosystem diversity.
- Open stack provides a software reference design for O-CU/O-DU architecture, interfaces, internal modules, and APIs, to promote and guide the open source software development.
- Open cloud presents O-Cloud reference design with the fundamental synchronization requirements and real life deployment recommendations.
- Testing and integration sets the criteria and guidelines for the formation of Open Testing and Integration Centers (OTICs), ensuring consistency and quality of the testing of O-RAN products and solutions.
Subsequent O-RAN releases will extend the MVP with additional features and functionalities based on continuing surveys and updates of operators’ deployment priorities.
28 New or Updated O-RAN Specifications Released since November 2020
On February 26, 2021, the O-RAN ALLIANCE published another 28 specification documents, including 10 new titles. For more details on the new specifications, please check this O-RAN blog post. To download O-RAN specifications, please proceed to www.o-ran.org/specifications.
O-RAN Open Summit Held on February 25, 2021 Available for Re-play
The O-RAN Open Summit on February 25, 2021 has gained attention with more than 2500 global visitors. The recording of Open Summit is available at the O-RAN website. The recording includes full content of the event, including five keynotes:
- Opening address - Alex Jinsung Choi, COO of O-RAN ALLIANCE and SVP Technology Strategy & Innovation of Deutsche Telekom
- Chairman address - Andre Fuetsch, Chairman of the O-RAN ALLIANCE and Chief Technology Officer of AT&T
- O-RAN Technical progress - Chih-Lin I, Co-Chair of O-RAN Technical Steering Committee and China Mobile Chief Scientist, Wireless Technologies, China Mobile Research Institute
- Testing and Integration Focus Group update - David Orloff, Co-chair of O-RAN Testing and Integration Focus Group, AT&T
- O-RAN Software Community update - Jack Murray, Co-Chair of OSC Technical Oversight Committee, AT&T
The event recording also includes the panel discussion on ‘Paths to O-RAN implementation’ providing valuable insights on possible ways towards open RAN introduction in the public mobile networks. The panelists represent a great variety of players in the O-RAN ecosystem: AT&T, NTT DOCOMO, Orange, TIM, O-RAN ALLIANCE, Intel, Keysight, ONF, Nokia and Radisys.
About O-RAN ALLIANCE
The O-RAN ALLIANCE is a world-wide community of more than 270 mobile operators, vendors, and research & academic institutions operating in the Radio Access Network (RAN) industry. As the RAN is an essential part of any mobile network, the O-RAN ALLIANCE’s mission is to re-shape the industry towards more intelligent, open, virtualized and fully interoperable mobile networks. The new O-RAN standards will enable a more competitive and vibrant RAN supplier ecosystem with faster innovation to improve user experience. O-RAN based mobile networks will at the same time improve the efficiency of RAN deployments as well as operations by the mobile operators. To achieve this, the O-RAN ALLIANCE publishes new RAN specifications, releases open software for the RAN, and supports its members in integration and testing of their implementations.
For more information please visit www.o-ran.org.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210316005553/en/
Contact information
O-RAN ALLIANCE PR Contact
Zbynek Dalecky
pr@o-ran.org
O-RAN ALLIANCE e.V.
Buschkauler Weg 27
53347 Alfter/Germany
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 08:02:00 EEST | Press release
Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization and further development of pridopidine in Europe and other select markets. Pridopidine is a potent and highly selective, orally administered sigma-1 receptor (S1R) agonist designed to regulate key neuroprotective mechanisms often impaired in neurodegenerative diseases such as HD and ALS. Under the terms of the agreement, Prilenia will receive an upfront payment of approximately €80 million plus up to €45 million in near-term development, regulatory, and commercial milestones. The total deal is valued at up to approximately €500 million in upfront and total milestone payments. In addition, Prilenia will receive tiered double-digit royalties on
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 08:00:00 EEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 12:36:00 EEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 20:00:00 EEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
Incyte to Highlight Early-Stage Oncology Data at American Association for Cancer Research Annual Meeting 202525.4.2025 15:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced that the Company will present new early-stage data from its oncology portfolio at the American Association of Cancer Research (AACR) Annual Meeting 2025 in Chicago, IL, from April 25–30. “At AACR we will be presenting data from early-stage programs across our oncology portfolio, including for patients with myeloproliferative neoplasms, ovarian cancer and other solid tumors,” said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. “These data will guide our approach as we advance our pipeline and seek to transform the treatment landscape for patients with cancer and myeloproliferative neoplasms.” Abstracts accepted for presentation at AACR include: Mini Symposium INCB177054 INCB177054: A Novel, Potent, Orally Bioavailable DGKα/ζ Dual Inhibitor Enhances T-Cell Function and Demonstrates Potent Antitumor Activity (Session Title: Novel Antitumor Agents. April 28, 4:50 p.m. – 5:05 p.m. ET (3:50 p.m. – 4:05 p.m. CT). Abstract #
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom